Analysis of the neutral polysaccharide fraction of MCP and its inhibitory activity on galectin-3
- 741 Downloads
The pH-modified citrus pectin (MCP) has been demonstrated to inhibit galectin-3 in cancer progression. The components and structures of MCP related to this inhibition remained unknown. In this paper, we fractionated MCP on DEAE-cellulose column into a homogenous neutral fraction MCP-N (about 20 kDa) and a pectin mixture fraction MCP-A (wide molecular distribution on Sepharose CL-6B chromatography). Both MCP-N and MCP-A inhibited hemagglutination mediated by galectin-3 with minimum inhibition concentration (MIC) 625 and 0.5 μg/ml, respectively. MCP-N was identified to be a type I arabinogalactan (AG-I) with a main chain of β-1→4-galactan. MCP-N was digested by α-L-arabinofuranosidase to give its main chain structure fraction (M-galactan, around 18 kDa), which was more active than the original molecule, MIC 50 μg/ml. The acidic degradation of M-galactan increased the inhibitory activity, MIC about 5 times lower than M-galactan. These results above showed that the functional motif of the β-1→4-galactan fragment might lie in the terminal residues rather than in the internal region of the chain. Therefore, MCP-N and its degraded products might be developed to new potential galectin-3 inhibitors. This is the first report concerning the fractionation of MCP and its components on galectin-3 inhibition. The information provided in this paper is valuable for screening more active galectin-3 inhibitors from natural polysaccharides.
KeywordsCitrus pectin Galectin-3 inhibitor Arabinogalactan Hemagglutination assay
This work was supported by the National Natural Science Foundation of China (Nos. 81173605, 31170770).
- 2.Prieto, V.G., Mourad-Zeidan, A.A., Melnikova, V., Johnson, M.M., Lopez, A., Diwan, A.H., Lazar, A.J.F., Shen, S.S., Zhang, P.S., Reed, J.A., Gershenwald, J.E., Raz, A., Bar-Eli, M.: Galectin-3 expression is associated with tumor progression and pattern of sun exposure in melanoma. Clin Canc Res 12, 6709–6715 (2006)CrossRefGoogle Scholar
- 4.Glinsky, V.V., Huflejt, M.E., Glinsky, G.V., Deutscher, S.L., Quinn, T.P.: Effects of Thomsen-Friedenreich antigen-specific peptide P-30 on β- galactoside-mediated homotypic aggregation and adhesion to the endothelium of MDA-MB-435 human breast carcinoma cells. Cancer Res 60, 2584–2588 (2000)PubMedGoogle Scholar
- 7.Glinsky, V.V., Kiriakova, G., Glinskii, O.V., Mossine, V.V., Mawhinney, T.P., Turk, J.R., Glinskii, A.B., Huxley, V.H., Price, J.E., Glinsky, G.V.: Synthetic galectin-3 inhibitor increases metastatic cancer cell sensitivity to taxol-induced apoptosis in vitro and in vivo. Neoplasia 11, 901–909 (2009)PubMedGoogle Scholar
- 9.Zou, J., Glinsky, V.V., Landon, L.A., Matthews, L., Deutscher, S.L.: Peptides specific to the galectin-3 carbohydrate recognition domain inhibit metastasis-associated cancer cell adhesion. Carcinog 26, 309–318 (2005)Google Scholar
- 10.Rabinovich, G.A., Cumashi, A., Bianco, G.A., Ciavardelli, D., Iurisci, I., D'Egidio, M., Piccolo, E., Tinari, N., Nifantiev, N., Iacobelli, S.: Synthetic lactulose amines: Novel class of anticancer agents that induce tumor-cell apoptosis and inhibit galectin-mediated homotypic cell aggregation and endothelial cell morphogenesis. Glycobiol 16, 210–220 (2006)CrossRefGoogle Scholar
- 14.Li, Y., Liu, L., Niu, Y., Feng, J., Sun, Y., Kong, X., Chen, Y., Chen, X., Gan, H., Cao, S., Mei, Q.: Modified apple polysaccharide prevents against tumorigenesis in a mouse model of colitis-associated colon cancer: role of galectin-3 and apoptosis in cancer prevention. Eur J Nutr 51, 107–117 (2012)Google Scholar
- 21.Kidd, P.M.: A new approach to metastatic cancer prevention: Modified Citrus Pectin (MCP), a unique pectin that blocks cell surface lectins. Alternative Med Rev 1, 4–10 (1996)Google Scholar